刊物主题:Surgical Oncology; Oncology; Abdominal Surgery; Gastroenterology; Cancer Research;
出版者:Springer Japan
ISSN:1436-3305
卷排序:20
文摘
BackgroundOral fluoropyrimidine S-1 contains tegafur, which is metabolized to 5-fluorouracil by cytochrome P450 2A6 (CYP2A6). We here examined associations between CYP2A6 polymorphisms and treatment outcomes of adjuvant S-1 in gastric cancer patients.